Kestra Medical Technologies (NASDAQ:KMTS) Stock Jumps 9.8% – Should You Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s stock price rose 9.8% on Thursday. The company traded as high as $27.76 and last traded at $27.9690. 112,802 shares traded hands during trading, a decline of 67% from the average daily volume of 341,014 shares. The stock had previously closed at $25.47.

Analyst Ratings Changes

Several research firms recently weighed in on KMTS. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. BTIG Research reissued a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.38.

Kestra Medical Technologies Price Performance

The firm’s 50-day moving average price is $26.39 and its 200-day moving average price is $23.52. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.62 billion, a PE ratio of -10.20 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The business had revenue of $30.97 million during the quarter. On average, equities analysts forecast that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In related news, insider Alfred J. Ford, Jr. sold 13,015 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.90, for a total transaction of $311,058.50. Following the completion of the transaction, the insider owned 105,839 shares in the company, valued at $2,529,552.10. The trade was a 10.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Webster sold 51,900 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the completion of the transaction, the insider directly owned 475,215 shares in the company, valued at $11,652,271.80. This trade represents a 9.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 246,928 shares of company stock valued at $5,997,473. 5.30% of the stock is owned by company insiders.

Institutional Trading of Kestra Medical Technologies

Several institutional investors and hedge funds have recently made changes to their positions in KMTS. Corient Private Wealth LP grew its stake in Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after acquiring an additional 44,839 shares in the last quarter. Sei Investments Co. increased its position in shares of Kestra Medical Technologies by 22.6% during the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares during the period. Spartan Wealth Advisory Services LLC purchased a new position in shares of Kestra Medical Technologies during the first quarter worth approximately $603,000. Quantinno Capital Management LP bought a new stake in shares of Kestra Medical Technologies during the first quarter valued at approximately $431,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Kestra Medical Technologies by 47.2% during the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after acquiring an additional 22,471 shares in the last quarter.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies designed to help protect patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, or WCD, which is intended to provide temporary protection for patients who may be at elevated risk of life-threatening ventricular arrhythmias.

The ASSURE system continuously monitors a patient’s heart rhythm and is designed to detect potentially dangerous arrhythmias, including ventricular tachycardia and ventricular fibrillation.